Literature DB >> 31674148

Genetic variability of serotonin pathway associated with schizophrenia onset, progression, and treatment.

Karin Hrovatin1, Tanja Kunej1, Vita Dolžan2.   

Abstract

Schizophrenia (SZ) onset and treatment outcome have important genetic components, however individual genes do not have strong effects on SZ phenotype. Therefore, it is important to use the pathway-based approach and study metabolic and signaling pathways, such as dopaminergic and serotonergic. Serotonin pathway has an important role in brain signaling, nevertheless, its role in SZ is not as thoroughly examined as that of dopamine pathway. In this study, we reviewed serotonin pathway genes and genetic variations associated with SZ, including variations at DNA, RNA, and epigenetic level. We obtained 30 serotonin pathway genes from Kyoto encyclopedia of genes and genomes and used these genes for the literature review. We extracted 20 protein coding serotonin pathway genes with genetic variations associated with SZ onset, development, and treatment from 31 research papers. Genes associated with SZ are present on all levels of serotonin pathway: serotonin synthesis, transport, receptor binding, intracellular signaling, and reuptake; however, regulatory genes are poorly researched. We summarized common challenges of genetic association studies and presented some solutions. The analysis of reported serotonin pathway-SZ associations revealed lack of information about certain serotonin pathway genes potentially associated with SZ. Furthermore, it is becoming clear that interactions among serotonin pathway genes and their regulators may bring further knowledge about their involvement in SZ.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  genetic association studies; genetic variations; pharamcogenetics; schizophrenia; serotonin pathway

Year:  2019        PMID: 31674148     DOI: 10.1002/ajmg.b.32766

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  3 in total

1.  Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia.

Authors:  Daniel R Garton; Ana R Montaño-Rodríguez; Soophie Olfat; Kärt Mätlik; Feride Eren; Laoise Casserly; Anastasios Damdimopoulos; Anne Panhelainen; L Lauriina Porokuokka; Jaakko J Kopra; Giorgio Turconi; Nadine Schweizer; Erika Bereczki; Fredrik Piehl; Göran Engberg; Simon Cervenka; T Petteri Piepponen; Fu-Ping Zhang; Petra Sipilä; Johan Jakobsson; Carl M Sellgren; Sophie Erhardt; Jaan-Olle Andressoo
Journal:  Mol Psychiatry       Date:  2022-05-26       Impact factor: 15.992

Review 2.  The Roles of Serotonin in Neuropsychiatric Disorders.

Authors:  Mahsa Pourhamzeh; Fahimeh Ghasemi Moravej; Mehrnoosh Arabi; Elahe Shahriari; Soraya Mehrabi; Richard Ward; Reza Ahadi; Mohammad Taghi Joghataei
Journal:  Cell Mol Neurobiol       Date:  2021-03-02       Impact factor: 5.046

3.  Serotonin-Related Functional Genetic Variants Affect the Occurrence of Psychiatric and Motor Adverse Events of Dopaminergic Treatment in Parkinson's Disease: A Retrospective Cohort Study.

Authors:  Sara Redenšek; Tanja Blagus; Maja Trošt; Vita Dolžan
Journal:  J Pers Med       Date:  2022-02-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.